PRINTER'S NO. 820
THE GENERAL ASSEMBLY OF PENNSYLVANIA
SENATE BILL
No.
675
Session of
2019
INTRODUCED BY BROOKS, BROWNE, HUTCHINSON, STEFANO AND K. WARD,
MAY 28, 2019
REFERRED TO HEALTH AND HUMAN SERVICES, MAY 28, 2019
AN ACT
Providing for certification of buprenorphine office-based
prescribers; limiting the use of buprenorphine; and imposing
powers and duties on the Department of Drug and Alcohol
Programs.
The General Assembly of the Commonwealth of Pennsylvania
hereby enacts as follows:
Section 1. Short title.
This act shall be known and may be cited as the Buprenorphine
Medically Assisted Treatment Act.
Section 2. Definitions.
The following words and phrases when used in this act shall
have the meanings given to them in this section unless the
context clearly indicates otherwise:
"Buprenorphine." A material, compound, mixture of
preparation containing buprenorphine or its salts used as
medically assisted treatment for opioid addiction.
"Buprenorphine office-based prescriber." A person that is
assigned a waiver from the Drug Enforcement Administration,
including a special identification number, commonly referred to
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
as the "X" DEA number, and provides office-based prescribing of
buprenorphine.
"Department." The Department of Drug and Alcohol Programs of
the Commonwealth.
Section 3. Buprenorphine medically assisted treatment.
(a) Certification.--The department shall establish a program
for certification of buprenorphine office-based prescribers as
qualified by training and experience to prescribe buprenorphine.
(b) Fee.--A buprenorphine office-based prescriber shall pay
a fee to the department in order to receive certification under
subsection (a). The amount of the fee shall not exceed $500
during the first year in which the fee may be imposed and
thereafter shall not exceed an amount sufficient to reimburse
the department for the administrative cost to administer and
enforce this act.
(c) Prohibition.--No buprenorphine office-based prescriber
shall prescribe buprenorphine to a patient unless all of the
following occur:
(1) The patient provides evidence demonstrating active
participation in an addiction treatment program licensed by
the department.
(2) The evidence of participation in the addiction
treatment program is documented in the patient's medical
record.
(3) The buprenorphine office-based prescriber is
certified by the department as provided under subsection (a).
(d) Violations.--
(1) The department shall report a violation of this act
to the appropriate licensure board.
(2) A person who violates this act and is licensed by a
20190SB0675PN0820 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
licensure board under another act shall be subject to
discipline by the licensure board under the other act for the
violation, including license suspension or revocation or an
appropriate fine or other penalty.
Section 4. Effective date.
This act shall take effect in 60 days.
20190SB0675PN0820 - 3 -
1
2
3
4
5
6